Drawing for REVPEM

USPTO serial 79394512

REVPEM

Reviewed by CopyMark Law Group

Reg. 7646846Status 700Registered
Filing date
Status date
Registration date
Jan 14, 2025
Examiner
ROACH, APRIL K
Law office
FILE REPOSITORY (FRANCONIA)

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with REVPEM?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

MAURY M. TEPPER, III

3724 Benson DriveRaleigh, NC 27609United States

Goods and services

ClassDescriptionStatusFirst use
005Anti-infectives; Anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for use in ophthalmology; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthma.ACTIVE—
044Collection and preservation of human blood; Collection and banking services for tissue and cells, namely, collection and banking of umbilical cord tissue perivascular stem cells; medical diagnostic services; medical treatment services, namely, treatment of cardiovascular, dermatological, ophthalmic, respiratory, gastro-intestinal, autoimmune, metabolic, endocrine, hematological, skeletal, immune, digestive, muscular, genitourinary, transplantation, nephrology, oncology and nervous systems; provision of medical information and data for diagnosis and medical treatmentACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Oct 10, 2025OPNXNOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB—
Sep 24, 2025OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Sep 24, 2025OPNRNOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB—
Aug 23, 2025FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Jul 31, 2025FICSFINAL DISPOSITION NOTICE SENT TO IB—
Jul 31, 2025FIMPFINAL DISPOSITION PROCESSED—
Apr 15, 2025FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Jan 14, 2025NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Jan 14, 2025R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Nov 26, 2024NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Nov 26, 2024PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Nov 20, 2024NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Oct 29, 2024EXPTEXPARTE APPEAL TERMINATED—
Oct 29, 2024CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Oct 28, 2024EXPIEX PARTE APPEAL-INSTITUTED—
Oct 28, 2024JURTJURISDICTION RESTORED TO EXAMINING ATTORNEY—
Oct 28, 2024EXAFEXPARTE APPEAL RECEIVED AT TTAB—
Oct 28, 2024TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Oct 28, 2024CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Oct 28, 2024ERFRTEAS REQUEST FOR RECONSIDERATION RECEIVED—
Oct 25, 2024GNFNNOTIFICATION OF FINAL REFUSAL EMAILED—
Oct 25, 2024GNFRFINAL REFUSAL E-MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Oct 25, 2024CNFRFINAL REFUSAL WRITTENA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Oct 2, 2024TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Oct 2, 2024CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Oct 2, 2024TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Sep 30, 2024RFNPREFUSAL PROCESSED BY IB—
Sep 4, 2024RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Sep 4, 2024RFRRREFUSAL PROCESSED BY MPU—
Sep 4, 2024RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Sep 3, 2024CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Aug 29, 2024DOCKASSIGNED TO EXAMINER—
May 13, 2024ECDRTEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS—
May 13, 2024ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
May 13, 2024REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
May 13, 2024CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
May 13, 2024COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
May 10, 2024MAFRAPPLICATION FILING RECEIPT MAILED—
May 10, 2024NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
May 2, 2024LIMILIMITATION FROM ORIGINAL APPLICATION ENTERED—
Apr 25, 2024REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance